Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR

Takashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, Satoru Maruyama, Shoichiro Mukai, Masakazu Tsutsumi, Jun Miki, Tomoya Okuno, Yuko Yoshio, Hiroaki Matsumoto, Toru Shimazui, Takehiko Segawa, Takashi Karashima, Kimihiko Masui, Fumimasa Fukuta, Kojiro Tashiro, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Tomohiro Fukui, Osamu Ogawa, Hiroshi Kitamura, Hiroyuki Nishiyama